The company said, “As previously announced, Equillium (EQ) had no further intention to continue development of itolizumab, therefore on September 30, 2025, Biocon and Equillium entered into an agreement to terminate their collaboration and license agreement and other agreements relating to itolizumab.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EQ:
- Equillium Files Prospectus for $75 Million Stock Sale
- Equillium files to sell 52.63M shares of common stock for holders
- Equillium Regains Nasdaq Compliance with Bid Price Rule
- Equillium price target lowered to $4 from $8 at Jefferies
- Equillium’s Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial Uncertainties